LGALS3 and atherosclerosis: These findings are consistent with the hypothesis that the Gal-3 might be used as a non-traditional risk factor for atherosclerosis and might participate in the pathological processes after LAA stroke, which suggests that therapies designed to suppress Gal-3 might have a role in the prevention and treatment of CVD.